At the Women's Health 2020 conference in June, Lee Cohen, MD, the director of the MGH Center for Women’s Mental Health, was honored as the recipient of the prestigious Vivian Pinn Award for Outstanding [...]
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on the practice of reproductive psychiatry amidst the COVID-19 pandemic with Ob.Gyn News on [...]
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on the new postpartum depression medication Zulresso (brexanolone) with Ob.Gyn News on August 20th, [...]
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on preventing postpartum depression with Ob.Gyn News on January 30, 2019 The last decade [...]
August 23, 2018 from ObGynNews The management of bipolar disorder during pregnancy is a critical clinical situation demanding great attention to issues such as reproductive safety of psychiatric medications used by women with bipolar disorder [...]
The following post was first published in OB/GYN News. Please see our OB/GYN News archives here. Publish date: April 23, 2018 The last two decades have seen an ever-growing number of reports on risks of fetal exposure to [...]
Dr. Lee S. Cohen recently shared news of a new screening application for postpartum depression with ObGyn News
The importance of postpartum depression, both in terms of its prevalence and the need for appropriate screening and effective treatments, has become an increasingly important area of focus for clinicians, patients, and policymakers. This derives [...]
The American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice recently published a revised opinion on screening for perinatal depression, recommending that “clinicians screen patients at least once during the perinatal period for [...]
Over the last decade, attention in the medical literature has gathered logarithmically to focus on potentially efficacious treatments for perinatal depression. Studies of relevant databases, editorials, and various reviews have addressed the reproductive safety concerns of antidepressant treatments, particularly selective serotonin reuptake inhibitors (SSRIs) on one hand, and the impact of untreated maternal psychiatric illness on fetal and maternal well-being on the other.
